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Metal ions are key elements in organisms’ life acting like cofactors of many enzymes
but they can also be potentially dangerous for the cell participating in redox reactions
that lead to the formation of reactive oxygen species (ROS). Any factor inducing or
limiting a metal dyshomeostasis, ROS production and cell injury may contribute to the
onset of neurodegenerative diseases or play a neuroprotective action. Transmissible
spongiform encephalopathies (TSEs), also known as prion diseases, are a group of fatal
neurodegenerative disorders affecting the central nervous system (CNS) of human and
other mammalian species. The causative agent of TSEs is believed to be the scrapie
prion protein PrPSc, the β sheet-rich pathogenic isoform produced by the conformational
conversion of the α-helix-rich physiological isoform PrPC. The peculiarity of PrPSc is its
ability to self-propagate in exponential fashion in cells and its tendency to precipitate
in insoluble and protease-resistance amyloid aggregates leading to neuronal cell death.
The expression “prion-like diseases” refers to a group of neurodegenerative diseases that
share some neuropathological features with prion diseases such as the involvement of
proteins (α-synuclein, amyloid β, and tau) able to precipitate producing amyloid deposits
following conformational change. High social impact diseases such as Alzheimer’s and
Parkinson’s belong to prion-like diseases. Accumulating evidence suggests that the
exposure to environmental metals is a risk factor for the development of prion and
prion-like diseases and that metal ions can directly bind to prion and prion-like proteins
affecting the amount of amyloid aggregates. The diet, source of metal ions but also of
natural antioxidant and chelating agents such as polyphenols, is an aspect to take into
account in addressing the issue of neurodegeneration. Epidemiological data suggest
that the Mediterranean diet, based on the abundant consumption of fresh vegetables
and on low intake of meat, could play a preventive or delaying role in prion and prion-like
neurodegenerative diseases. In this review, metal role in the onset of prion and prion-like
diseases is dealt with from a nutritional, cellular, and molecular point of view.
Keywords: metal dyshomeostasis, Mediterranean diet, transmissible spongiform encephalopathies, Alzheimer’s
disease, Parkinson’s disease, synucleinopathies, prion, synuclein
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INTRODUCTION
Many neurodegenerative diseases such as Alzheimer’s disease
(AD), synucleinopathies (including Parkinson’s disease, PD),
Huntington’s disease (HD), amyotrophic lateral sclerosis
(ALS), and frontotemporal dementia can be included under
the definition of “prion-like disease” as they share some
neuropathological features with the prion diseases (transmissible
spongiform encephalopathies, TSEs). Overall, the prion and
prion-like diseases have high social impact and cost as they
include the most common age-related disorders. The proteins
directly involved in prion-like diseases [Amyloid β (Aβ)
for AD, tau for tauopathies, and α-synuclein (α-syn) for
synucleinopathies] show similarities to prion protein in terms of
the mechanism of seeding (Yamamoto et al., 2005; Nonaka et al.,
2010) and spreading (Frost et al., 2009; Hansen et al., 2011) and of
cell interaction modalities (Yamamoto et al., 2005; Nonaka et al.,
2010). In the central nervous system (CNS), prion-like proteins
can aggregate in an ordered “cross-β” assembly following a
“nucleated growth” process and they can produce fibers that
precipitate forming intracellular amyloid-like inclusions or
extracellular amyloid deposits associated to neurodegeneration.
Recently, Prusiner and collaborators demonstrated the ability of
α-syn to serially propagate the infection both in vitro and in vivo
systems defining it as a new prion protein (Prusiner et al., 2015;
see Section “α-syn as NewHuman Prion” for more details). Prion
proteins, α-syn and prion-like proteins (Aβ and tau) can directly
interact with several metal ions affecting the conformation of the
protein and its tendency to aggregate in oligomers and fibrils.
Epidemiological studies show that the occupational exposure
to environmental metals such as manganese, copper, lead, iron,
mercury, zinc, and aluminum is a risk factor for the development
of neurodegenerative and prion-like diseases (Zayed et al., 1990;
Rybicki et al., 1993; Gorell et al., 1999; Benedetto et al., 2009;
Fukushima et al., 2010; Cannon and Greenamyre, 2011). On
the other hand, metal ions and especially transition metals are
key elements in organisms’ life. They act like cofactors of many
enzymes and are essential in cell respiration and metabolism
due to their ability to accept or donate electrons passing from
a reduced to an oxidized state (Barnham and Bush, 2014).
However, transition metal ions can also be potentially dangerous
for the cell as they can participate in redox reactions leading to
the formation of reactive oxygen species (ROS) that can oxidize
intracellular proteins, lipids, and nucleic acids. In particular,
the radical-mediated oxidation of a protein can strongly affect
its molecular structure by the generation of protein-protein
linkages, the oxidation of amino acid side chains and even by the
fragmentation of the polypeptide chain and the level of oxidized
proteins increases during aging in many animals (for detail refer
to Stadtman, 2006; Valensin et al., 2016).
For this reason, in the CNS any factor which induces a metal
dyshomeostasis and the consequent production of ROS and cell
injury may contribute to the onset of these neurodegenerative
diseases. On the contrary, any factor able to reduce metal
dyshomeostasis and to limit the production of ROS and free
radicals can play a neuroprotective action. In addition to these
general aspects, metal ions can have a more direct involvement in
prion and prion-like neurodegenerative diseases for their ability
to directly bind to prion and prion-like proteins and to affect the
amount of amyloid aggregates.
The diet, source of metal ions and antioxidant agents such as
polyphenols for the organism, is an aspect to take into account
in addressing the issue of neurodegeneration. In recent decades,
the food consumption in Western countries has undergone a
rapid change that quickly led to the shift from a seasonal diet
based on the consumption of fresh vegetable food and some
meat derived from extensive farming to a massive consumption
of packaged food and meat resulting from factory farms where
animals are usually fed with a non-natural diet and subjected
to drug treatments. The so-called mad cow disease is a striking
example of how the change in farming method can contribute
to the spread of prion diseases. In addition, the use of pesticides
and herbicides in intensive agriculture determines the inclusion
in the food chain of chemical substances that potentially can have
harmful effects in the CNS even reacting with prion and prion-
like proteins. Such changes in human diet lead to a variation
in the nutrient intake that may affect the antioxidant and
metal bioavailability in the CNS. Epidemiological data suggest
that the Mediterranean diet (MeDi), based on the abundant
consumption of fresh vegetables and on low intake of meat,
could play a preventive or delaying role in prion and prion-like
neurodegenerative diseases.
In this review, metal role in the onset of prion diseases (TSEs
and synucleinopathies) and in AD, as an example of prion-like
disease, is dealt with from a nutritional, cellular and molecular
point of view.
PRION PROTEIN AS A MODEL PROTEIN
FOR PRION DISEASES
The cellular prion protein (PrPC) is a highly conserved
cell surface glycosylphosphatidylinositol (GPI)-anchored
glycoprotein expressed in all mammalian tissues, particularly in
the CNS (Harris, 1999). A conformationally-modified isoform
of PrPC called “Scrapie” (PrPSc) is the major component
of prions, the infectious particles at the basis of rare and
inexorably fatal neurodegenerative disorders, called TSEs or
prion diseases. TSEs develop on genetic, sporadic, or infectious
grounds (Prusiner, 1998), and include bovine spongiform
encephalophathy (BSE) in cattle, scrapie in sheep and goat,
chronic wasting disease (CWD) in cervids and Creutzfeldt-Jacob
disease (CJD) and Gerstmann-Sträussler-Scheinker syndrome
in humans. TSEs are characterized by spongiform modifications
in the brain, amyloid deposits with neuronal loss, and synaptic
dysfunction. PrPC and PrPSc though sharing the same primary
structure and post-translational modifications (Stahl et al.,
1993), are characterized by a different secondary structure.
The β sheet-rich overall structure confers to PrPSc different
physico-chemical and biologic features, including increased
tendency to aggregate and resistance to proteolysis, the ability
to self-propagate in a host organism and the acquisition of
novel neurotoxic properties (Prusiner, 1998). The peculiarity
of PrPSc is its ability to self-propagate in exponential fashion
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in cells, by acting as a model for the protein misfolding (Soto,
2012). PrPC is tethered to the outside of the plasma membrane
through its GPI anchor in plasma membrane subdomains
called lipids rafts (Stahl et al., 1987) and it can shift to caveolae
mediating signal transduction events (Toni et al., 2006). PrPC
NMR structure shows a flexible and disordered N-terminal
domain (NT) (23–124 residues) and a C-terminal globular
domain (CT) (125–228) that contains three α-helices, two
short anti-parallel β-strands, and a short C-terminal tail (Zahn
et al., 2000). This structure is stabilized by a single disulfide
bond between Cys-179 and Cys-214 (human sequence). The
NT contains five highly conserved proline- and glycine-rich
octapeptide repeats (OR) (Harris, 1999). In spite of PrPC’s
intimate involvement in TSE prion propagation, its function
in cell physiology remains enigmatic, also because PrP-KO
mice, in which the gene coding for PrPC was ablated (PrP-
KO) by different gene-targeting strategies, showed no defects
in embryonic and postnatal development and no behavioral
alterations (Büeler et al., 1992; Manson et al., 1994; Mallucci et al.,
2002) and only marginal phenotypes under normal conditions
were observed in these mice (Criado et al., 2005; Nazor et al.,
2007). These phenotypes could be due to the activation of
compensatory mechanisms that hide the PrP-KO phenotype
under physiological conditions and makes it detectable only
under specific stress conditions or during aging (for a review
see Ref. Peggion et al., 2016). However, several functions have
been attributed to PrPC (Peggion et al., 2016), some of which
related to the ability of this protein to bind transition metal
ions.
PRION PROTEIN BINDS TRANSITION
METALS
Several metal ions are able to bind with different affinities to the
PrPC, affecting its conformation and tendency to aggregate and
influencing PrPC/PrPSc conversion. The OR region of PrPC is the
main metal binding site that can interact with Cu2+, Zn2+, and
Mn2+ (Jackson et al., 2001; Walter et al., 2007; Brown, 2011) and
it confers high stability to the protein (Benetti et al., 2014).
At physiological pH, PrPC is able to bind four Cu2+ ions with
high affinity in specific sites of OR region (Brown et al., 1997;
Thompsett et al., 2005) and two additional Cu2+ at residues 96
and 111 with lower affinity (Jones et al., 2004). Many studies
suggest the involvement of PrPC in copper homeostasis (Brown
et al., 1997; Wong et al., 2001a) as extracellular Cu2+ ions
stimulate PrPC endocytosis (Pauly and Harris, 1998; Brown
and Harris, 2003), particularly at the pre-synaptic membrane
(Vassallo and Herms, 2003) and regulate PrPC expression (Toni
et al., 2005).
PrPC has been associated with metal-dependent enzymatic
functions (Brown et al., 1999; Rachidi et al., 2003) and,
consequently, with the enhancement of cell anti-oxidant
potentials (White et al., 1999; Mitteregger et al., 2007; Peggion
et al., 2016). Recently, a Cu2+-dependent neuroprotective role
of PrPC by mediating N-methyl-d-aspartate (NMDA) receptor-
nitrosylation (Gasperini et al., 2015) has been demonstrated.
Experimental evidence supports the involvement of copper
not only in PrP physiology but also in its pathology. In fact, the
binding of copper to PrP would make the protein a relatively easy
target of metal-catalyzed oxidation and it would lead to structural
modifications that favor the PrPC–PrPSc conversion and the
following protein aggregation. Experimental evidence shows that
both histidine and methionine residues can be oxydated and
involved in these events (Requena et al., 2001; Colombo et al.,
2009). Currently available data are sometimes conflicting and
does not allow a clear interpretation of Cu2+ role in prion
disease. In vitro and in vivo experiments show that the addiction
of Cu2+ induces the conversion of PrPC into PrPSc, increases
the protease resistance and the infectivity of the protein, and
overall accelerates prion disease (Pauly and Harris, 1998; Qin
et al., 2000; Quaglio et al., 2001; Kuczius et al., 2004; Kim et al.,
2005; Canello et al., 2012), while Cu2+ chelation delays the
beginning of the disease (Sigurdsson et al., 2003; Siggs et al.,
2012). On the other hand, similar experiments indicate that
the presence of Cu2+ inhibits conversion of PrPC into PrPSc
and consequently its accumulation, delaying the onset of the
disease in infected cells (Hijazi et al., 2003; Bocharova et al.,
2005; Orem et al., 2006; Mitteregger et al., 2009). One possible
explanation of these contrasting results comes from in vitro
studies suggesting that Cu2+ ions can exert different effects on
PrPC/PrPSc conversion depending on whether the template is
constituted by soluble recombinant/purified PrP proteins or by
preformed fibrils (Liu et al., 2007). Moreover, it has been reported
that point mutations in PrPC gene may cause coordinational
changes at the copper site, favoring the conversion of PrPC
into PrPSc (D’Angelo et al., 2012; Giachin et al., 2015). Other
possible explanations come from analyses of the ecosystems that
support defined clusters of sporadic TSE. These studies suggest
that Cu ions, such as Zn ions, can exert different effects on
PrPC/PrPSc conversion depending on whether these transition
metals are free or bound to scavenger co-factors in the CNS
(Purdey, 2000).
TSEs are characterized by dys-metal homeostasis and by
increased oxidative stress. Elevated levels of reactive oxygen
intermediate species, nitric oxide and lipid peroxidation markers
were detected both in the brains of mice infected with scrapie
strains (Wong et al., 2001b) and in sporadic CJD frontal cortex
homogenates (Freixes et al., 2006). The continuous conversion
of PrPC into PrPSc deprives neurons from the control of metal
balance. However, whether the imbalance of metals is the cause
or the consequence of TSEs is not yet known. PrPC protein
is able to bind Mn2+ at His96 and in the C-terminal region
between residues 91 and 230 (Treiber et al., 2007; Brazier
et al., 2008), protecting cells against Mn2+-induced oxidative
stress (Choi et al., 2007). Manganese induces spontaneous PrPSc
conversion (Brown et al., 2000) and increases the infectivity of
PrPSc in cultured cells (Davies and Brown, 2009), while Mn2+
chelation decreases the amount of PrPSc present in infected
mice brains (Brazier et al., 2010). Mn2+ levels are increased in
blood and brain samples from subjects affect by BSE, scrapie,
CJD, and from experimentally infected mice. Moreover, the
increased manganese levels were inversely correlated to copper
concentrations (Wong et al., 2001c; Thackray et al., 2002).
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The influence of the environment on prion diseases is
supported by studies indicating a geographical increase of CJD
prevalence in people who have lived in a region of Slovakia
where manganese is a major pollutant. High Mn2+ levels and
increased Mn2+/Cu2+ ratios were observed in these CJD brains
(Slivarichová et al., 2011). The link between Mn2+ and prion
infection was also evidenced at the cellular level (Pass et al., 2015).
PrPC binds also Zn2+ regulating its homeostasis, although
with lower affinity and at low concentrations than Cu2+.
Zinc, as copper, increases endocytosis of the prion protein
causing the metal internalization and its elimination from the
synaptic cleft. It has been also speculated that PrPC acts as a
sensor to monitor Zn2+ extracellular levels that may trigger
a PrPC-induced signaling (Rana et al., 2009). Moreover, PrPC
may affect Zn2+ uptake via α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (Watt et al., 2013).
Studies conducted on several PrPC-peptides demonstrate that
Zn2+ induces the increase of PrPSc aggregation while in the
presence of full length PrPC, Zn2+caused a reduction of PrPSc
deposition (Jobling et al., 2001; Kenward et al., 2007).
PrPC contributes to maintaining iron homeostasis in the
brain by regulating the iron uptake through the interaction
with transferrin receptor pathway (Waheed et al., 2002) and
by working as a ferric reductase in the transport of Fe3+
from endosomes to the cytosolic ferritin (Singh et al., 2015).
Iron dyshomeostasis involves an incorrect nerve myelinizzation,
altered neurotransmission, and affect bioenergetic processes
resulting in neuronal death.
In sporadic-CJD brains, iron is sequestered in heat- and
SDS-stable ferritin-PrPSc protein complexes, inducing an iron
deficiency phenotype (Singh et al., 2009). So, despite the
increased redox-activity of iron, its sequestration in complex
aggregate proteins leads to a functional iron deficit. Moreover,
Basu et al. (2007) demonstrated that the exposure to a source of
reduced iron, such as inorganic ferrous chloride (FeCl2) induced
the conversion of PrPC to PrPSc implicating a role for this metal
in the generation and propagation of PrPSc.
SYNUCLEINOPATHIES AS PRION
DISEASES
The term “synucleinopathies” defines a group of human
neurodegenerative disorders characterized by the presence of
amyloidogenic α-synuclein (α-syn) inclusions that can occur in
neurons and glia cells of the central and peripheral nervous
system. These high social impact diseases include PD, Parkinson’s
disease dementia (PDD), dementia with Lewy bodies (DLB),
multiple system atrophy (MSA), and a number of less well-
characterized neuroaxonal dystrophies (Goedert, 2001).
Patients affected by synucleinopathies can show both
motor and non-motor symptoms. PD is a progressive
neurological disorder characterized by depression, anosmia, sleep
disturbances, bradykinesia, resting tremor, rigidity, and postural
instability (Fahn, 2003). Dementia is a frequent complication of
PD characterized by deficits in attention, recognition memory
and visual perception, by sleep disturbances, hallucinations and
paranoid ideas (Perry et al., 1990; McKeith and Mosimann, 2004;
Vann Jones and O’Brien, 2014; Garcia-Ptacek and Kramberger,
2016). MSA (also previously referred as Shy–Drager syndrome,
olivopontocerebellar atrophy, and striatonigral degeneration) is
characterized by muscle rigidity, tremor, cerebellar dysfunctions
that include ataxia, and impairment of the autonomic nervous
system (Goedert, 2001).
The amyloidogenic α-syn inclusions are intracellular
proteinaceous bodies containing aggregates of
hyperphosphorylated α-syn rich in β-sheets (Baba et al.,
1998; Wakabayashi et al., 1998; Spillantini, 1999; Fujiwara et al.,
2002) that are called Lewy bodies (LBs) and Lewy neurites (LNs)
in PD, PDD, and LDB (Spillantini et al., 1997), glial cytoplasmic
inclusions in MSA (Gai et al., 1998), and axonal spheroids in
neuroaxonal dystrophies (Newell et al., 1999). A causative role
for α-syn in the development of synucleinopathies has been
established in PD via the discovery of mutations in the α-syn
gene SNCA (A30P, E46K, H50Q, G51D, and A53T) resulting
in autosomal-dominant PD (Kruger et al., 1998; Zarranz et al.,
2004; Appel-Cresswell et al., 2013; Lesage et al., 2013; Proukakis
et al., 2013; Pasanen et al., 2014).
α-syn belongs to synuclein family together with β- and γ-
syns. These proteins are particularly expressed at the level of the
central (α- and β-syn) and peripheral (γ-syn) nervous system.
In the CNS, α-syn is expressed in both neurons and glial cells
and in neurons it is mainly localized in the cytoplasm and in
presynaptic terminals, but a nuclear localization has been also
reported (Vivacqua et al., 2011). The syn family members were
sequenced in species representative of all vertebrates and the
comparative analysis of amino acid sequences suggests that syns
are evolutionarily conserved and fulfill important physiological
functions (Toni and Cioni, 2015; Toni et al., 2016; Figure 1).
However, the exact physiological roles of these proteins have not
been fully clarified yet.
Human α-syn is a naturally unfolded protein composed of
24 negatively charged residues (Asp and Glu) that belongs
to the class of “intrinsically disordered proteins” (Uversky
et al., 2008; Figure 1). Its primary structure can be subdivided
in the N-terminal region (NT) (1–60), the NAC (non-
amyloid component) segment (61–95), and C-terminal region
(96–140) (CT) (Figure 1). As in the case of the prion protein
PrPC/PrPSc, α-syn can exist in different conformations in the
cell, passing from an unstructured conformation in solution
to a high α helix percentages (63–71%) when linked to
the phospholipid vesicles (Davidson et al., 1998) or to a
major anti-parallel β-sheet conformation when aggregated into
fibrils (Weinreb et al., 1996; El-Agnaf et al., 1998; Narhi
et al., 1999). The NT can assume α-helix conformation
binding to lipid membranes (Davidson et al., 1998) and
from these features probably depend the involvement of α-
syn in vesicle trafficking (Burré et al., 2010), neurotransmitter
release and synaptic plasticity (Abeliovich et al., 2000; Murphy
et al., 2000). The NAC segment is a highly hydrophobic
region containing the amino acid sequence GVTAVAQKTVE
capable of acquire antiparallel β-sheet conformation responsible
for the aggregation and precipitation of α-syn proteins
in insoluble fibrils (Narhi et al., 1999). The CT is an
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FIGURE 1 | Alignment of the α-syn amino acid sequences of representative species of teleost fish (Xiphophorus maculatus, accession number
XP_005812724), amphibians (Xenopus laevis, NP_001080623), reptiles (Anolis carolinensis, XP_003221349), birds (Taeniopygia guttata, NP_001041718),
and mammals (Homo sapiens, NP_001139526). Sequences were aligned with Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Asterisks indicate
identity of amino acids; double dots indicate amino acids with the same polarity or size; dots indicate semiconserved substitutions. Cu2+ binding sites are indicated
by arrowheads, Cu+ binding regions are underlined, manganese, and iron binding sites are highlighted in gray and Ca2+ binding regions are double underlined.
Negatively charged residues are indicated in bold characters. Circled P letter indicates residues whose phosphorylation increases the α-syn binding affinity for Cu2+,
Pb2+, and Fe2+.
unstructured negatively charged region able to bind metal
ions and proteins that probably acts as a scaffold for the
recruitment of additional protein to the membrane (Eliezer et al.,
2001).
α-SYN AS A NEW HUMAN PRION
A series of experimental evidence collected in the last 15
years supports the existence of a “prion like” mechanism
in synucleinopathies according to which the α-syn pathology
can spread between cells following neuroanatomical traits and
the amyloidogenic β-syn can act as a template to guide
the conversion of soluble, natively, unfolded α-syn to a
conformationally-altered, aggregated form able to transmits from
cell-to-cell. Recently, Prusiner and co-workers have defined the
α-syn as a new human prion (Prusiner et al., 2015). Main
experimental results are summarized in Figure 2 (for further
details refer to the figure caption).
Pre-formed α-syn fibrils (PFF) rich in β-sheets with
morphologies and structural characteristics similar to those
extracted from LBs can be obtained in vitro from the
polymerization of α-syn unstructured monomers. The α-syn
fibrillation is a nucleated polymerization process in which the
unfolded monomer undergoes self-assembly to form oligomeric
intermediates (nuclei) at the onset of aggregation, followed by
monomer accretion and fibril growth. A similar mechanism has
been described in PrP aggregation process. PFF addiction to the
culture medium induced the formation of protein aggregates in
the cytoplasm of neuron cells (Figure 2A).
Studies of Braak et al. (2006) performed on numerous
post-mortem cases of idiopathic PD support the capacity of
pathological α-syn to spread in the human CNS suggesting the
existence of a path of diffusion of the α-syn pathology from the
dorsal motor nucleus of the vagus and in the anterior olfactory
structure to the other brain regions (Figure 2B).
In order that a “prion-like” disease can be spread in the CNS,
the causative agent must be transferred from one cell to another
to induce the formation of amyloidogenic inclusions.
Monomeric and oligomeric forms of α-syn have been detected
in human body fluids (plasma, saliva and cerebrospinal fluid;
Borghi et al., 2000; El-Agnaf et al., 2003, 2006; Tokuda et al.,
2006; Vivacqua et al., 2016) and in vitro and in vivo experiments
showed that α-syn can be released from a donor cell, be taken
up by a recipient cell, and then seed aggregation of endogenous
α-syn within the recipient cell (Figures 2C–E).
Transgenic (Tg) mice expressing wild type (WT) human
α-syn (h α-syn), or mutant A53T h α-syn M83 mice have been
employed to provide compelling evidence for the detrimental
role of α-syn inclusion formation in CNS neurons (Figure 2F).
These studies highlight how the expression of the mutant A53T
h α-syn in mice leads to neurodegeneration by promoting the
formation of filamentous inclusions (Figures 2F1–3).
In order to further investigate whether α-syn can be spread
with a “prion like” mechanism, several studies have been
conducted based on the experimental approach used in the
study of prion disease transmission: solutions containing α-syn
protein of various origins have been administered to cell cultures
or injected in WT or Tg mice to evaluate whether such
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FIGURE 2 | Schematic overview of the main evidence in support of the prion nature of human α-syn. (A) In vitro experiments, recombinant α-syn monomer
can generate amylodogenic fibrils able to infect cultured cells. (B) In the idiopathic PD the formation of proteinaceous inclusion bodies begins in the dorsal motor
nucleus of the vagus nerve and advances from there essentially upwards through susceptible regions of the medulla oblongata, pontine tegmentum, midbrain, and
basal forebrain until it reaches the cerebral cortex (circled numbers refer to the synuclein progression in the CNS). (C) 12–22 years after transplantation into the
striatum of individuals with PD, grafted nigral neurons developed α-syn positive LBs that stained positively also for ubiquitin providing evidence that the disease can
propagate from host to graft cells. (D) Dopaminergic neurons extracted from the ventral mesencephalon of E12.5 C57BL/6 mice were grafted to the striatum of
6-week old transgenic mice overexpressing h α-syn. After 6 months, the grafted dopaminergic neurons showed putative intracellular h α-syn positive punctae
demonstrating in vivo transfer of α-syn between host cells and grafted dopaminergic neurons. (E) Cell-produced α-syn is secreted via an exosomal calcium-dependent
(Continued)
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FIGURE 2 | Continued
mechanism. The extracellular α-syn is taken up by cells through endocytosis and inside the cell interacts with intracellular α-syn forming dimers. (F) (1) Homozygous
TgM83+/+ mice expressing A53T h α-syn in CNS neurons developed intracytoplasmic neuronal α-syn inclusions and a severe and complex motor impairment leading
to paralysis and death starting from the 8th month; (2) hemizygous TgM83+/− mice developed the same symptoms between 22 and 28 months of age; (3) Tg mice
that express wild type h α-syn developed no motor impairment and revealed normal neuropil staining pattern expected for the protein up to the age of 28 months; (4)
TgM83+/+ mice inoculated with brain homogenates from sick 12 or 18 month-old TgM83+/+ mice showed the characteristic motor clinical signs of illness after 97
days post-inoculation (dpi); (5) bigenic Tg mice (M83+/−; Gfap-luc) inoculated with brain homogenates from spontaneously ill 10 month-old TgM83+/+ sample
showed symptoms of synucleinopathies 160 dpi; (6) C57B1/6S ∆α-syn mice (presenting a deletion of the α-syn locus) inoculated with brain homogenates from sick,
12 or 18 month-old TgM83+/+ mice, show no signs of disease and were still alive and healthy 14 months post-inoculation; (7) brain homogenate from healthy 2
month-old TgM83+/+ inoculated in TgM83+/+ mice did not induce an acceleration in the onset of α-syn pathology in TgM83+/+ mice; (8) Tg mice (M83+/−;
Gfap-luc) inoculated with brain homogenate from two independent confirmed cases of MSA began to exhibit signs of neurologic illness, most commonly ataxia and
circling behavior, at about 90 dpi; (9) WT C57BL6/C3H mice inoculated with synthetic pre-formed α-syn fibrils (PFF) obtained in vitro from recombinant mouse or h
α-syn progressively developed α-syn cytoplasmatic accumulation at 30 dpi that evolved in dense perinuclear LB-like inclusions by 90 and 180 dpi; (10) α-syn−/− mice
inoculated with PFF did not develop α-syn deposits; (11) no phosphorylated α-syn, ubiquitin or p62-positive pathology was observed in the brain of WT C57BL/6J
mice inoculated with human or mouse α-syn monomer; (12) WT C57BL/6 mice inoculated with nigral LB-enriched fractions from post mortem PD brain resulted in
progressive nigrostriatal neurodegeneration and diffusely α-syn accumulation within nigral neurons and anatomically interconnected regions by 4 up to 17 months
post-inoculation; (13) WT C57BL/6 mice inoculated with nigral non-LB fractions from post mortem PD brain showed no nigrostriatal degeneration; (14) WT C57BL/6
mice inoculated with α-syn-immunodepleted nigral LB fractions from post mortem PD brain showed no phospho α-syn-positive cells and any evidence of pathology;
(15) α-syn−/− C57Bl6Sv129 mice inoculated with nigral LB fractions from post mortem PD brain did not produce any α-syn pathology or evidence of nigrostriatal
lesions; (16) WT C57BL/6J mice brain injected with DLB insoluble fraction from post mortem PD brain showed in the 50% of cases immunopositive structures for
anti-phosphorylated α-syn at 15 months post injection (17–21) recombinant full length mouse fibrillar α-syn (mfib) or fibrillar human 21-140 α-syn (hfib) were injected in
the hind limb muscle of 2 month-old TgM83+/+ (17), of TgM83+/− (18–19), of WT C3H/C57BL6 (20), or of α-syn−/− (21) mice. The injected mice died or had to be
killed due to paralysis within 57–88 (TgM83+/+) or 121 (TgM83+/−) dpi. Mice also developed α-syn inclusion pathology that was nearly indistinguishable
morphologically in anatomic distribution from that seen in aged (>8 month-old) untreated TgM83+/+ mice. Four of the seven mice that had sciatic nerve transection
showed no motor deficits 200 dpi (19). On the contrary, WT and α-syn−/− mice developed no motor phenotype or α-syn pathology at 12 months post injection
(20–21); (22) The injection of human 171–82 α-syn in TgM83+/+ mice resulted in delayed onset of disease (120 dpi) and incomplete penetrance of the pathology.
(G) Inoculation with MSA brain homogenate in TgM83+/− mice caused CNS dysfunction and the accumulation of large aggregates of phosphorylated α-syn and
widespread astrocytic gliosis with mean incubation periods of 106–143 dpi (primary transmission). The inoculations in TgM83+/− mice with brain homogenates from
ill TgM83+/− mice previously inoculated with MSA showed a shorter incubation period (92–113) (secondary transmission). The brain homogenate from MSA patients
and from both serially infected TgM83+/− mice were able to infect cultured cells. Figure drawings refers to the following references: (A; Desplats et al., 2009; Luk
et al., 2009; Emmanouilidou et al., 2010; Nonaka et al., 2010; Volpicelli-Daley et al., 2011; Narkiewicz et al., 2014); (B; Braak et al., 2006); (C; Kordower et al., 2008;
Li et al., 2008, 2010; Kurowska et al., 2011); (D; Hansen et al., 2011); (E; Emmanouilidou et al., 2010; Hansen et al., 2011); [F: 1–3 (Giasson et al., 2002); 4, 6, 7
(Mougenot et al., 2012); 5, 8 (Watts et al., 2013); 9, 10 (Luk et al., 2012); 11, 16 (Masuda-Suzukake et al., 2013); 12–15 (Recasens and Dehay, 2014); 17–21 (Sacino
et al., 2014)]; (G; Prusiner et al., 2015).
administration may induce the formation of LB-like inclusion
(Figures 2A,F4–21,G). Both recombinant α-syn (in the form of
monomers, oligomers or fibrils; Figures 2F9,10,16–21) and brain
homogenate from murine (Figures 2F4–7) or human subjects
affected by α-syn pathologies (Figures 2F8,11–15) have been
used.
On the whole these studies suggest that the injection of a
lysate containing pathological α-syn in the brain of WT mice
or Tg A53T h α-syn mice, or even in the hind limb peripheral
nerve of Tg A53T h α-syn mice induces/accelerates the onset
of the disease depending on the amount of pathological α-syn
administrated and that α-syn expression in the host animal is
necessary for the development of the pathology. Finally, the serial
propagation of the infectivity in α-syn pathology, a prerequisite
for a prion agent, was demonstrated by primary and secondary
transmission in TgM83+/− mice using pathological α-syn
from MSA brain homogenates (Figure 2G). Collectively, these
studies strongly support the prion nature of the pathological
h α-syn.
ROLE OF METALS IN
SYNUCLEINOPATHIES
The involvement of metals in synucleinopathies is suggested by
epidemiological studies showing a positive correlation between
the occupational exposure to specific metals and the onset of PD
and manganism, a disorder that shares many phenomenological
features with PD, such as cognitive decline, psychiatric alteration
and movement abnormalities (Zayed et al., 1990; Rybicki et al.,
1993; Gorell et al., 1999; Benedetto et al., 2009; Fukushima
et al., 2010). Elevated levels of several metal ions have been
reported in the substantia nigra of people affected by PD (Gorell
et al., 1997; Ayton and Lei, 2014). Furthermore, iron and
aluminum have been detected in the LBs demonstrating the
accumulation of metal ions in α-syn amyloidogenic aggregation
(Dexter et al., 1991; Hirsch et al., 1991). In contrast, a lower
concentration of copper was detected in brain regions of PD
patients characterized by an accumulation of iron, if compared
with controls (Dexter et al., 1991; Davies et al., 2014). Several
lines of evidence support the possible involvement of iron in
the pathogenesis of PD and specific reviews have been published
on the subject (Götz et al., 2004; Mounsey and Teismann,
2012).
The risk of developing synucleinopathies increases with age.
Interestingly, also the concentration of iron in the brain increases
with age (Acosta-Cabronero et al., 2016; Pirpamer et al., 2016).
A recent study has demonstrated an age-induced increase in the
expression of both divalent metal transporter (DMT1) and α-syn
in mice cells (Lu et al., 2016). This result describes a cellular
scenario in which the cytoplasmic amount of both divalent metal
ions and α-syn increase with age.
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Manymetal ions (mono, di and trivalent) can bind to α-syn by
means of its negative charged residues, reducing their repulsion
and affecting the protein tendency to aggregate in fibrils. This
feature, also observed in PrP prion protein, can be closely related
to the onset and development of synucleinopathies. Metal ions
show different binding affinities for α-syn but the binding sites
are similar for the majority of metal ions. Generally, divalent
cations (such as Fe2+, Mn2+, Co2+, Ni2+, Ca2+, and Cu2+) bind
to the CT of α-syn (Nielsen et al., 2001; Lowe et al., 2004; Binolfi
et al., 2006) but binding sites for copper have been described also
in NT and NAC segment (Camponeschi et al., 2013; Moriarty
et al., 2014). Amongmetal ions, copper shows the highest binding
affinity estimated in the µM range and it can bind to residues
Met-1, Asp-2, His-50, Asp-119, Asp-121, and Glu-123 (Binolfi
et al., 2006, 2012; Rodríguez et al., 2016; Figure 1). Manganese
and iron can bind to residues Asp-121, Asn-122, and Glu-123
with an affinity in the range 1–50mM (Golts et al., 2002; Binolfi
et al., 2006) whereas the Fe3+ shows an affinity of 1.2× 10 13 M−1
(Peng et al., 2010).
The binding between metal ions and α-syn can be affected
by pH-values (Drew et al., 2008) and protein modification such
as phosphorylation (Lu et al., 2011), acetylation (Moriarty et al.,
2014), and puntiformmutation (Drew et al., 2009). At acidic pH-
values, Cu2+ binding sites shift toward the CT (Drew et al., 2008).
The phosphorylation of residues Ser-129 and Tyr-125 increases
the binding affinity for Cu2+, Pb2+, and Fe2+ (but not Fe3+) and
determine a shift of the binding sites from the NT to CT (Lu et al.,
2011). Among PD linked mutations, the A30P mutation favors
the binding of Cu2+ to His50 whereas E46K, A53T did not seem
to affect copper binding (Drew et al., 2009).
The rate of α-syn fibril formation in vitro was significantly
accelerated by several divalent and trivalent metal ions such
as Cu2+, Fe3+, Co3+, and Mn2+ (Uversky et al., 2001). The
addition of Cu2+ to α-syn leads to a dynamically stable β-sheet
conformation that serves as a nucleation point for a second- β
strand (Rose et al., 2011) producing compact conformers toxic
for the cell (Curtain et al., 2015). Moreover, µM concentrations
of Fe3+ induce the formation of large SDS-resistant cytotoxic
oligomers capable of forming pores in the lipid bilayer when
added to the cells (Kostka et al., 2008). Interestingly, different
metal ions induce the formation of α-syn oligomerswith different
characteristics: Co3+ and Ca2+ produced annular oligomers
(Lowe et al., 2004) whereas other metal ions (Ni2+, Fe3+, Cu2+,
Mg2+, Cd2+, Zn2+) induced spherical oligomers (Nielsen et al.,
2001; Figure 1D).
The potential involvement of α-syn in oxidative stress
is an important issue as synucleinopathies, and in general
neurodegenerative diseases, are associated with high levels
of oxidative stress in the brain (Eskici and Axelsen, 2012;
Schildknecht et al., 2013; Dixon and Stockwell, 2014). However,
conflicting evidences on the causative or protective role of α-syn
aggregation in ROS generation are available. On the one hand,
it was shown that the oxidation of copper bound to α-syn
can lead to the formation of hydrogen peroxide that exhibits a
cytotoxic behavior in the cell (Lucas et al., 2010;Wang et al., 2010)
promoting events proposed to be strongly related to the etiology
of PD (Dell’Acqua et al., 2015) such as dityrosine crosslink (Lucas
et al., 2010), dopamine oxidation (Meloni and Vasak, 2011), and
methionine sulfoxidation (Ayton et al., 2013). On the other hand,
a recent study showed that the copper/α-syn binding can exert
a protective role against ROS. Pedersen et al. (2016) found that
the levels of ROS and the rate at which they are generated, are
significantly reduced when copper is bound to α-syn (and Aβ)
particularly when the protein is in oligomeric and fibrillar form.
These observations suggest that copper bound to the protein is
less accessible to the solvent and therefore less capable of reacting
with ascorbate, resulting in a reduced ROS formation, but further
studies are necessary to elucidate this issue.
Recently, new data has been obtained on the interaction
between iron and α-syn. In cell cultures the over expression
of α-syn induced increased levels of intracellular iron and
resulted in partial redistribution of iron from the cytoplasm
to perinuclear inclusions (Ortega et al., 2016). Moreover, the
expression of A53T mutant h α-syn aggravates Fe2+ mediated
toxicity which results in an increased oxidative stress and DNA
damage (Chew et al., 2011). Interestingly, intranasal treatment
with desferrioxamine (DFO), a chelator widely used in clinical
settings for the treatment of iron overload, down-regulated the
expression of both α-syn and divalentmetal transporter 1(DMT1;
Guo et al., 2016).
Which exactly is the physiological function of the binding
between metal ions and α-syn and whether it has an evolutionary
significance is not yet completely clarified. The comparative
analysis of α-syn amino acid sequences of representative species
of teleost fish (Xiphophorus maculatus), amphibians (Xenopus
laevis), reptiles (Anolis carolinensis), birds (Taeniopygia guttata),
and mammals (Homo sapiens) shows that most of the negatively
charged amino acids and sites able to bind copper, iron,
and manganese ions in mammals are well-conserved among
vertebrate species (Figure 1): Met-1, Asp-2 are conserved in all
the five sequences analyzed, whereas, Asn-122, and Glu-123 are
conserved in all tetrapoda species considered. Asp-119 is not
conserved only in X. laevis in which it is substituted by Asn, His-
50 lacks in X. maculatus and A. carolinensis, whereas Asp-121
is conserved only in X. maculatus. Interestingly, Tyr-125 and
Ser-129, residues whose phosphorylation increases the affinity
for Cu2+, Pb2+, and Fe2+, are perfectly conserved among the
tetrapoda species analyzed.
Although there is variability in the number of syn isoforms
in non-mammalian vertebrates (Toni and Cioni, 2015) and more
data and detailed studies are necessary for a thorough analysis,
the data here reviewed suggest that the binding of metal ions to
α-synmay be involved in evolutionary conserved, as not yet clear,
physiological functions and that the concomitant presence in the
cytoplasm of high amount of α-syn protein and high metal ions
concentrations makes the cell more prone to the formation of
amyloid aggregates and the organism more susceptible to disease
development.
The amount ofmetal ions in the brain undergo changes during
the course of life (Acosta-Cabronero et al., 2016; Pirpamer et al.,
2016), and the metal ions concentration may vary in the different
brain regions (Ayton and Lei, 2014). Given the broad spectrum
of effects of metal ions on the cell physiology, this means that in
the course of human life the change in metal ions concentration
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can make the nervous system more prone and susceptible to the
onset of neurodegenerative prion diseases. In this sense, themetal
intake through the diet could influence the onset of prion and
prion-like neurodegenerative diseases.
ALZHEIMER’S DISEASE AS A PRION-LIKE
DISEASE
Alzheimer’s disease (AD) is a neurodegenerative disorder
involving progressive cortical and hippocampal neuron loss,
clinically characterized by progressive and irreversible cognitive
deficits and behavioral alterations that affect memory, learning
ability, and the quality of life. There are two distinct clinical
manifestations of AD, familial and sporadic, both characterized
by the aggregation of misfolded proteins, inflammation, and
metabolic failure. Although AD is a genetically complex
autosomal dominant disease, caused by mutations in the amyloid
precursor protein (APP) gene, presenilin 1 (PSEN1), or presenilin
2 (PSEN2; Bertram et al., 2010), the majority of AD cases are
sporadic. Pathologically, AD is characterized by amyloid deposits
that consist of extracellular aggregated Aβ, neurofibrillary tangles
(NFTs) composed by the hyperphosphorylated tau protein, and
by neuronal losses (Hardy and Higgins, 1992). The Aβ peptides
are produced by the cleavage of the APP through the so called
“amyloidogenic pathway.” In this way, the sequential activity
of β-secretase (BACE1; Cole and Vassar, 2008) and γ-secretase,
a multiprotein complex that contains both PSEN1 or PSEN2
(Steiner, 2008), produces APP fragments of different length (39–
42 amino acids) among which Aβ42 is considered particularly
neurotoxic and more prone to self-aggregation than shorter
peptides.
Research conducted over the past two decades have shown
many similarities between Aβ and prion properties and for this
reason Aβ is generally included among the prion-like proteins.
Recently, comprehensive reviews on this fascinating subject have
been published to which refer for in-depth details and specific
references (Tatarnikova et al., 2015; Ugalde et al., 2016; Walker
et al., 2016). Aβ, like PrP, may undergo conformational changes
assuming a tertiary structure rich in β sheets that promotes the
self-assembly of the protein in oligomeric and fibrillar aggregates
with neurotoxic properties (Haass and Selkoe, 2007; Klein,
2013). Interestingly, insoluble Aβ seeds are relatively resistant
to proteinase K (PK) whereas Aβ soluble fraction is largely
PK sensitive and it loses its seeding activity after PK digestion
(Langer et al., 2011).
Several experiments based on the intracerebral injection of
AD brain homogenate in non-human primates and in transgenic
mice and rats (Baker et al., 1993; Meyer-Luehmann et al., 2006;
Rosen et al., 2012) showed an increase in the amount of Aβ
deposits in the receiving brain that augmented with longer
incubation time and with higher concentration of the injected
homogenates. On the contrary, the use of both control brain
homogenate and AD brain homogenate in which Aβ had been
depleted by antibodies did not induce the Aβ accumulation
(Meyer-Luehmann et al., 2006; Duran-Aniotz et al., 2014),
suggesting that the pathological Aβ contained in the AD brain
can be the promoting agent. In support of this hypothesis, the
deposition of Aβ can be observed also after the injection of high
concentrations of multimeric synthetic Aβ accompanied by long
periods of incubation (Stöhr et al., 2012).
The deposits of seed-induced Aβ, initially found only in
tissues near the site of injection, gradually propagate along
axons to different brain regions with stereotypic temporal-spatial
spreading patterns which are partly reminiscent of the spreading
characteristics of prions. From this point of view, the deposition
of the pathological protein in AD can be explained by the initial
formation of protein seeds early in pathogenesis, followed by a
prion-like spread of misfolding and aggregation events along the
neuroanatomical pathways.
ROLE OF METALS IN AD
Although genetic, biochemical, and neuropathological data
indicate that amyloid formation plays a central role in AD
pathogenesis (Selkoe, 2001), the aetiopathology of this disease
remains unclear. Compelling evidence suggest the existence of
a correlation between the imbalance of metal homeostasis in
the brain and the pathogenesis of AD. Transition metals could
participate in AD pathogenesis by interacting with Aβ peptide,
promoting its aggregation and facilitating ROS production
and oxidative stress. Focal accumulation of Zn, Cu, and Fe
might also deprive other brain tissues of these essential metals,
leading to aberrant neuronal function. The total amount of
copper (390µM), zinc (1055µM), and iron (940µM) have been
reported to be increased in AD brain as compared to normal age-
matched samples (copper, 70µM; zinc, 350µM; iron, 340µM;
Lovell et al., 1998). At a cellular level, the analysis of the amount
of metal ions in samples from AD patients revealed increased
zinc and iron (Deibel et al., 1996; Bouras et al., 1997; Duce et al.,
2010), decreased levels of copper (Bouras et al., 1997; Smith et al.,
1997; Duce et al., 2010) and imbalances in aluminum, silicium,
and mercury.
Concerning Zinc, Bush et al. (1994) provided the first
biochemical evidence that this metal ion is able to bind Aβ
and to cause its aggregation and precipitation initiating the
plaque formation. Zinc also interferes with Aβ processing, by
inhibiting γ-secretase activity and increasing PS1 expression
(Lammich et al., 1999). Through the activation of tau-kinases,
Zn can also impact on tau-related neurotoxicity (Mo et al.,
2009). The dyshomeostasis of Zn in the brain can lead to an
enhanced susceptibility to the excitotoxicity of glutamate and to
oxidative stress (Oteiza et al., 1995; Takeda et al., 2004), being
this metal an inhibitory neuromodulator of glutamate release in
the hippocampus and antagonizing the catalytic properties of the
redox-active transition metals.
Copper, like Zn, is synaptically released and acts as a potent
mediator of Aβ aggregation (Mantyh et al., 1993). It binds
with high affinity to an amino terminal tyrosine residue in
Aβ inducing its oligomerization and neurotoxicity. Moreover,
the elevated copper amount was detected in amyloid plaques.
The cytotoxicity induced by the Cu-Aβ complex involves also
oxidative stress events, as this complex catalytically generates
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hydrogen peroxide (Huang et al., 1999), through the reduction
of Cu2+ to Cu+, accompanied with the oxidation of endogenous
molecules such as thiols, cytochrome c oxidase, ascorbate and
lipids (Turnbull et al., 2001; Puglielli et al., 2005). The resulting
lipid peroxidation leads to the formation of peroxyl radicals,
which once formed, can then be rearranged into compounds
like malondialdehyde (MDA; Jomova and Valko, 2011) and
4-hydroxy-2-nonenal (HNE), detected at higher levels in AD
brain and AD transgenic mouse models (Haeffner et al., 2005;
Nelson and Alkon, 2005). However, although Cu2+ is increased
in amyloid plaques, it is decreased in AD neuronal tissue which
in turn could deprive Cu-binding proteins such as superoxide
dismutase and ceruloplasmin and impairs their function.
Copper also influences the fate of APP processing, given
its participation in APP processing into non-amyloidogenic
derivatives while its deficiency reduces Aβ degradation
(Cater et al., 2008).
Concerning Fe, its deposition in neurons causes oxidative
stress via the Fenton reaction, producing abnormalities in RNA,
yielding a great reduction in protein synthesis and initiating
several Fe-induced apoptotic signaling pathways (Salvador and
Oteiza, 2011). Fe indirectly damages proteins such as Ca2+-
ATPase, glutamate transporter, Na+/K+-ATPase as well as
N-methyl-D-aspartate (NMDA) receptor, and lipids such as
cholesterol ceramides and unsaturated fatty acids through the
formation of hydrogen peroxide and the hydroxyl radical (Kaplán
et al., 1997; Mark et al., 1997; Muñoz et al., 2011; Shinkyo
et al., 2011). Elevated cellular Fe levels can cause cell death
independently of ROS toxicity by the phenomenon known as
ferroptosis, a type of Ras-related cell death pathway (Dixon et al.,
2012), while its increased concentration at synapses may also
leads to increased Aβ production by altering its processing. In
fact iron can act by decreasing the protein furin, whichmodulates
γ–secretase activity, and increased iron concentration favor
γ–secretase activity and enhances the amyloidogenic pathway.
Although metal dyshomeostasis in AD is primarily due to metal
sequestration by amyloid plaques and NFTs, the disruption
of the vesicular trafficking has also to be considered since it
prevents metal ion containing vesicles to arrive at the axon
terminal. The disruption of axonal transport affects also the
mitochondrial transport preventing the replacement of the old
organelles with the new ones and the production of the energy
required for the reuptake of Cu/Zn from the postsynaptic
neuron. The acquisition of knowledge of the role of metals in
AD neurodegeneration has prompted the discovery of metal-
chelating compounds (such as desferrioxamine and deferiprone)
conjugated to nanoparticles favoring their passing through the
blood-brain barrier that in vivo prevent the toxic actions of
transition metals (Li et al., 2011). Presently, only one family of
metal-binding agents, PBT2 [5,7-dichloro-2-((dimethylamino)-
methyl)-8-hydroxyquinoline], is testing in clinical trials for the
treatment of AD. PBT2 binds excesses of copper, zinc, and
possibly iron in the brain, thereby diminishing the amount of
amyloid plaque formation and relocating these metal ions to
depleted cellular and neuronal compartments (Crouch et al.,
2011).
MEDITERRANEAN DIET, PRION AND
PRION-LIKE DISEASES, AND
NEURODEGENERATION
The traditional Mediterranean diet (MeDi) is characterized
by an abundant consumption of plant foods, a moderate
intake of fish and wine, and low intakes of meats and dairy
products, with extra-virgin olive oil as the main fat source.
Adherence to the MeDi has also been associated with a lower
risks of AD, PD, dementia, and cognitive decline (Scarmeas
et al., 2006, 2009; Féart et al., 2009; Singh et al., 2014) while
no epidemiological data are available for the rare sporadic
CJD. Human epidemiological study, such as the Northern
Manhattan Study have confirmed that MeDi is associated with
a lower white matter hyperintensities (VMH) burden evaluated
by magnetic resonance imaging, a marker of small vessel
damage and neurodegeneration (Gardener et al., 2012). Many
studies have demonstrated that MeDi is associated with a
significant reduction in AD risk. Results based on observational
studies (Valls-Pedret and Ros, 2013) and long-term randomized
clinical trials have clearly shown that a correlation between
MeDi and AD exists with strong level of scientific evidence
(Valls-Pedret et al., 2015).
Higher MeDi adherence was also associated with reduced
odds for PD, after adjustment for all covariates while on the
contrary, lower MeDi adherence was associated with earlier PD
age-at-onset (Alcalay et al., 2012).
In PD, there is considerable evidence for ROS-mediated
damage in post mortem brain samples as well as in other tissues,
even outside of the central nervous system. Oxidative damage to
nucleic acids, lipids and proteins in both the brain and peripheral
tissues in human PD has been clearly evidenced (Sanders and
Greenamyre, 2013).
Even if the neurobiological basis of the relationship between
the MeDi to brain health has not been elucidated yet, various
specific nutrient components of this diet have been examined in
relation to cognitive performance including dietary fatty acids,
antioxidants, amount of fruits and vegetables consumption,
vitamins (particularly B6, B12, and folate; Smith and Blumenthal,
2010). The MeDi is a very complex eating pattern, with a
multitude of single components that could cause beneficial
neuroprotective effects (Jacobs et al., 2009; Gotsis et al., 2015).
In the midst of this multitude, plant polyphenols, which occur
mainly in fruit, vegetables, and wine (Manach et al., 2004) have
recently shown to possess beneficial effects with regard to overall
health, as well as cognitive functions (Baur and Sinclair, 2006;
Witte et al., 2014). Plant polyphenols represent an abundant
class of plant secondary metabolites found in herbal-rich food
and beverages, with no <8000 phenolic structures having been
identified in plants (Tsao, 2010).
For example, oleuropein aglycone (OLE), the main
polyphenol in the extra-virgin olive oil has clearly showed
to ameliorate memory dysfunction, neuronal loss and
neurodegenerative damages in AD animal models (Grossi
et al., 2014). Dietary supplementation of OLE (50 mg/kg
of diet), strongly improved the cognitive performance
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of young/middle-aged TgCRND8 mice, a model of Aβ
deposition. In these mice, a reduced β-amyloid levels and
plaque deposits was associated with a strong increase of
autophagic markers expression and of lysosomal activity (Grossi
et al., 2013). In human population, serum concentration of some
phytochemicals, characteristic of the Mediterranean diet (such
as lutein, zeaxantin, and β-carotene), were consistently related
to better cognition functions in the Georgia centenarian study
(Johnson et al., 2013).
Much effort has been undertaken in the way of understanding
the neuroprotective effects of polyphenols, using both in vitro
and in vivo models (Johnson et al., 2013). The molecular
mechanisms of their neuroprotective actions can be classified
as anti-inflammatory, antioxidant (free radical scavenging
and metal chelation), anti-amyloid action, or through direct
modulation of cell signaling pathways, such asmetalloproteinases
inhibition or their activity on transcription factors such as
NF-kB (Gomes et al., 2008; Crascì et al., 2016). Their
ability to simultaneously and synergistically modulate multiple
molecular targets, suggests a greater potential also for therapeutic
intervention in AD and PD (Grodstein et al., 2007; Johnson et al.,
2008). Since transition metal and particularly iron have been
clearly involved in neurodegenerative disorders and aging (Ward
et al., 2014), in the next section, we focus on the free radical
scavenging and metal chelation effects of some polyphenols.
POLYPHENOLS AS METAL CHELATORS
AND FREE RADICAL SCAVENGERS
Polyphenols are well-established metal chelators and some of
them possess the ability to bind and chelate many different
bivalent metals, such as Cu2+, Zn2+, and Fe2+ (Singh et al.,
2008; Mandel et al., 2011). In this way, the rate of Fenton
reaction directly diminishes and the oxidation caused by reactive
hydroxyls radicals can be prevented (Perron and Brumaghim,
2009). Moreover, polyphenols decrease metal absorption by
exerting their chelating activities also into the small intestine
(Landete, 2012). In humans participating in the PAQUID
cohort study, higher levels of polyphenols (flavonoids) were
associated with ∼50% reduction of the risk to develop dementia
(Commenges et al., 2000).
In animal models, it has been clearly demonstrated that
various polyphenols, capable to chelate divalent metals and with
antioxidants activities, possess neuroprotective effects. Dairam
et al. (2008) have observed that curcumin modulates iron in
rat-brain homogenates. In a rat model of Parkinson’s disease,
curcumin has shown neuroprotective effects by decreasing
neuron degeneration (Du et al., 2012). Epigallocatechin Gallate
(EGCG) is the most effective antioxidant polyphenol in green
tea and there is clear evidence that EGCG is very effective in
metal chelation of Fe2+, Zn2+ and Cu2+ (Chan et al., 2016).
In SH-SY5Y neuroblastoma cells, EGCG has exhibited stronger
iron chelation compared to desferrioxamine (Reznichenko et al.,
2006).
At the molecular level, different polyphenols have shown
to inhibit Aβ42 fibril formation by directly interacting both
with Aβ42 and transition metals. For example, glycosylated
polyphenols (such as verbascoside present in the olive tree) and
their esterified derivatives regulate metal-free and metal-induced
Aβ42 aggregation and disaggregation at 50 µM concentrations
(Korshavn et al., 2015).
EGCG, at 100µM completely inhibited the formation of
Aβ42 fibril and was capable to reduce the amount of fibrils
present when EGCG was added demonstrating its ability of
remodeling preformed fibrils (Chan et al., 2016). Curcumin,
one of the principal polyphenols in turmeric (Curcuma longa)
exhibited moderate metal chelation and antioxidant activity,
and it is a known inhibitor of Aβ fibril formation in vitro
(Ono et al., 2004).
Red wine is famous for its polyphenol content. The
major polyphenols found in red wine extracts include
resveratrol, quercetin, catechin, epicatechin, tyrosol, gallic
acid, and procyanidins. Many different in vitro studies have
described the potent free radical scavenging effects of red
wine polyphenols, including direct scavenging of reactive
oxygen and nitrogen species, such as peroxides, superoxide,
the hydroxyl radical, and the peroxynitrite anion, as well as
sequestering of highly redox-active metal ions (Wang and
Brumaghim, 2011). Treatment of neuronal and astrocytic cell
lines with these polyphenolic compounds suppressed ROS
production and significantly improved cell viability (Martin
et al., 2011, 2013). Resveratrol, mostly present in berries,
grapes and wine, was protective in human neuroblastoma
cells exposed to Aβ or to Aβ-metal complexes through its
scavenging properties (Granzotto and Zatta, 2011). Several
polyphenols present in wine have been demonstrated to
protect mitochondria from ROS damages in in vitro studies.
These include resveratrol, quercetin, anthocyanidins, and
proanthocyanidins (Fernández-Moriano et al., 2015). Moreover,
resveratrol administration, as a dietary supplement, significantly
attenuates 6-hydroxydopamine-induced oxidative damage, and
dopamine depletion in a rat model of Parkinson’s disease (Khan
et al., 2010).
Since resveratrol is able to penetrate the blood–brain
barrier and exert strong neuroprotective effects, even at low
concentrations, it has been used in a clinical trial that has
currently completed phase II in 120 patients with possible AD
diagnosis (NCT01504854). Ongoing trials are investigating the
efficacy of a mixture of grape polyphenols in mild cognitive
impairments (MCI) and moderate AD (i.e., NCT02502253).
To date, although some polyphenols can efficiently cross
the blood-brain barrier, the literature suggests that single
polyphenol may not attain concentrations within the brain that
are sufficient to exert an effective metal chelation and free radical
scavenger activities. Nevertheless, MeDi is characterized by a
high consumption of many different polyphenols-rich foods and
beverages that may exert their neuroprotective effects in a time-
dependent manner. Epidemiological studies suggest that the
activities of these complex mixtures of multitarget compounds
could be protective and really effective at preventing or delaying
prion-like diseases with a high prevalence in the population,
such as AD and PD (Alcalay et al., 2012; Pelletier et al.,
2015).
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CONCLUSIONS
Neurodegenerative diseases such as TSEs, synucleinopathies,
AD, Huntington’s diseases, and ALS belong to the prion
and prion-like diseases, disorders in which specific proteins
precipitate in amyloid aggregates in the nervous system as a
result of conformational change. Among these diseases, AD
and PD are disorders of concern for their high social impact
and cost as they are the most widespread neurodegenerative
diseases in the populations of Western European countries and
the USA. Epidemiological studies and experimental evidence
at the cellular and biochemical level show the influence
of the dyshomeostasis of metals in the onset of such
neurodegenerative diseases. It is noteworthy that different
risks of developing AD and PD have been associated with
different nutritional habitus. Among them, the Mediterranean
diet was found to be the most protective, with significant
reduced odds for PD and AD. This diet is characterized by
a very high content of different multifunctional polyphenols
capable to bind metals (transition metals in particular) and
amyloid aggregates, acting by specific regulators of aggregation
and cytotoxicity of metal-free and metal-associated prion
and prion-like proteins. Many of these polyphenols can
cross the blood-brain barrier and serve as specific and
multitarget compounds capable to regulate ROS damages,
inflammation and aggregation of misfolded proteins in neuronal
tissues.
Having classified the major neurodegenerative diseases within
the classes of prion and prion-like diseases implies that we must
accept the idea that nutritional factors are capable to modify the
mechanisms of neuronal damage induced by prion and prion-like
proteins and that the Mediterranean diet can exert a protective
role in these diseases.
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